Corps Capital Advisors LLC Makes New Investment in AbbVie Inc. (NYSE:ABBV)

Corps Capital Advisors LLC purchased a new stake in AbbVie Inc. (NYSE:ABBV - Free Report) in the 4th quarter, according to its most recent filing with the SEC. The institutional investor purchased 9,145 shares of the company's stock, valued at approximately $1,625,000. AbbVie makes up about 1.6% of Corps Capital Advisors LLC's investment portfolio, making the stock its 19th largest holding.

Several other large investors have also recently added to or reduced their stakes in the stock. Groupama Asset Managment grew its stake in shares of AbbVie by 40.3% during the third quarter. Groupama Asset Managment now owns 135,749 shares of the company's stock valued at $27,000 after acquiring an additional 38,974 shares in the last quarter. RPg Family Wealth Advisory LLC acquired a new stake in shares of AbbVie during the third quarter valued at about $28,000. Fiduciary Advisors Inc. acquired a new stake in shares of AbbVie during the fourth quarter valued at about $29,000. Retirement Wealth Solutions LLC acquired a new position in AbbVie in the fourth quarter worth about $35,000. Finally, Mizuho Securities Co. Ltd. grew its stake in AbbVie by 100.0% in the third quarter. Mizuho Securities Co. Ltd. now owns 200 shares of the company's stock worth $39,000 after purchasing an additional 100 shares in the last quarter. 70.23% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other AbbVie news, SVP Kevin K. Buckbee sold 1,800 shares of AbbVie stock in a transaction that occurred on Monday, December 16th. The shares were sold at an average price of $172.24, for a total transaction of $310,032.00. Following the transaction, the senior vice president now directly owns 6,983 shares in the company, valued at approximately $1,202,751.92. The trade was a 20.49 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Corporate insiders own 0.25% of the company's stock.

AbbVie Price Performance

AbbVie stock traded up $1.15 during mid-day trading on Friday, hitting $202.03. The company's stock had a trading volume of 5,879,957 shares, compared to its average volume of 5,370,269. The company has a quick ratio of 0.54, a current ratio of 0.66 and a debt-to-equity ratio of 17.94. The stock has a market capitalization of $356.64 billion, a P/E ratio of 84.18, a P/E/G ratio of 1.61 and a beta of 0.58. AbbVie Inc. has a twelve month low of $153.58 and a twelve month high of $207.32. The stock's fifty day moving average price is $181.25 and its two-hundred day moving average price is $186.41.

AbbVie (NYSE:ABBV - Get Free Report) last posted its quarterly earnings results on Friday, January 31st. The company reported $2.16 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.98 by ($0.82). AbbVie had a return on equity of 296.28% and a net margin of 7.59%. During the same quarter last year, the business posted $2.79 earnings per share. Research analysts forecast that AbbVie Inc. will post 12.31 earnings per share for the current year.

AbbVie Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, May 15th. Shareholders of record on Tuesday, April 15th will be given a dividend of $1.64 per share. This represents a $6.56 annualized dividend and a yield of 3.25%. The ex-dividend date of this dividend is Tuesday, April 15th. AbbVie's payout ratio is 273.33%.

Wall Street Analysts Forecast Growth

A number of equities analysts recently commented on ABBV shares. Guggenheim lifted their price target on AbbVie from $212.00 to $214.00 and gave the stock a "buy" rating in a research note on Monday, February 3rd. Morgan Stanley raised their target price on shares of AbbVie from $224.00 to $239.00 and gave the stock an "overweight" rating in a report on Monday, February 3rd. Bank of America reissued a "neutral" rating and issued a $191.00 target price on shares of AbbVie in a report on Tuesday, December 10th. Leerink Partnrs raised AbbVie from a "hold" rating to a "strong-buy" rating in a report on Friday, November 22nd. Finally, UBS Group lifted their price target on AbbVie from $181.00 to $190.00 and gave the company a "neutral" rating in a report on Monday, February 3rd. Five equities research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and two have issued a strong buy rating to the company's stock. According to data from MarketBeat, AbbVie has an average rating of "Moderate Buy" and an average target price of $208.35.

About AbbVie

AbbVie Inc discovers, develops, manufactures, and sells pharmaceuticals worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, and pyoderma gangrenosum; Skyrizi to treat moderate to severe plaque psoriasis, psoriatic disease, and Crohn's disease; Rinvoq to treat rheumatoid and psoriatic arthritis, ankylosing spondylitis, atopic dermatitis, axial spondyloarthropathy, ulcerative colitis, and Crohn's disease; Imbruvica for the treatment of adult patients with blood cancers; Epkinly to treat lymphoma; Elahere to treat cancer; and Venclexta/Venclyxto to treat blood cancers.